Hepatic Bypass Modality describes a method of hormone administration that intentionally circumvents the portal circulation and the initial metabolic breakdown that occurs upon first-pass transit through the liver. This clinical strategy is employed to deliver the active hormone directly into the systemic circulation, ensuring a higher bioavailability and reducing the liver’s exposure to high concentrations of the compound. The modality is crucial for managing the downstream effects on hepatic protein synthesis.
Origin
This pharmacological principle developed in response to the clinical observation that oral administration of certain steroid hormones could lead to undesirable alterations in liver-produced proteins, such as clotting factors and Sex Hormone Binding Globulin (SHBG). The etymological roots lie in the anatomical term ‘hepatic’ (referring to the liver) and ‘bypass’ (to go around).
Mechanism
The primary mechanism relies on non-oral routes of delivery, most commonly transdermal, sublingual, or parenteral (injections/pellets). These routes allow the hormone to enter the bloodstream via peripheral capillaries or lymphatic channels, distributing it to target tissues before it eventually reaches the liver for catabolism. This approach maintains a more physiological ratio of active hormone to its metabolites and minimizes supraphysiological induction of hepatic enzymes.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.